I'm LongbridgeAI, I can summarize articles.TD Cowen maintains a Hold rating on Stryker with a $298 price target, implying an 8.7% upside from the September 21 close. The firm cites soft spots in the U.S. orthopedic market and ongoing utilization pressure as key challenges. Despite strong demand for capital products, anticipated growth is considered factored into the current valuation, justifying the Hold stance based on updated earnings projections and a lowered P/E multiple.
TD Cowen maintained their Hold rating on Stryker's stock with a price target of $298.00.
The price target implies an upside of 8.7% from the Sep 21 close of $274.19.
Key takeaways from the analyst note
Market Challenges: Stryker is facing "soft spots" in performance, particularly in the U.S. orthopedic market, which has led analysts to recalibrate their revenue estimates and pricing targets. This reflects ongoing utilization pressure and competitive dynamics that may hinder growth.
Valuation Reflection: The current price target of $298 per share is deemed reasonable given the updated earnings projections and a lowered price-to-earnings multiple. The valuation adjustments suggest that while Stryker has strong demand for capital products, the anticipated growth is already factored into the stock price, justifying the Hold rating.
Explore more price target data and ratings for Stryker on the .